Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS
NCT ID: NCT00467610
Last Updated: 2014-10-24
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
TERMINATED
Clinical Phase
PHASE2
Total Enrollment
6 participants
Study Classification
INTERVENTIONAL
Study Start Date
2007-05-31
Study Completion Date
2009-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a Phase II, open-label clinical trial examining the role of Panhematin® in patients with MDS. The objective of this study is to evaluate the safety and efficacy of Panhematin® (hematin for injection) in the treatment of adult patients (≥ 18 years of age) with low-risk MDS.
The study will be conducted on an outpatient basis and will consist of the following:
* A Screening Period (within 28 days of the Day 1)
* Screening bone marrow aspiration and biopsy up to 60 days prior to receiving study medication
* An 8-week Treatment Period (Days 1 through 4 of Week 1, and weekly visits during Weeks 2 through 8); partial and complete responders in any of the three cell lines may continue treatment for an additional 4 weeks
* A 6-month Post treatment Follow-up Period (monthly clinic visits during Weeks 12 40)
The study will be conducted on an outpatient basis and will consist of the following:
* A Screening Period (within 28 days of the Day 1)
* Screening bone marrow aspiration and biopsy up to 60 days prior to receiving study medication
* An 8-week Treatment Period (Days 1 through 4 of Week 1, and weekly visits during Weeks 2 through 8); partial and complete responders in any of the three cell lines may continue treatment for an additional 4 weeks
* A 6-month Post treatment Follow-up Period (monthly clinic visits during Weeks 12 40)
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
NCT06847867
Myelodysplastic Syndromes
RECRUITING
PHASE2
Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes
NCT02281084
Myelodysplastic Syndromes
COMPLETED
PHASE2
Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)
NCT01842646
Myelodysplastic Syndrome (MDS)
Chronic Myelomonocytic Leukemia (CMML)
COMPLETED
PHASE2
An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome
NCT01751867
Myelodysplastic Syndrome
COMPLETED
PHASE3
Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS
NCT04055844
Acute Myeloid Leukemia
Myeloid and Monocytic Leukemia
Myelodysplastic Syndromes
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The myelodysplastic syndromes (MDS), a diverse group of hematopoietic stem cell (HSC) disorders, are characterized by ineffective hematopoiesis that manifest clinically as anemia, neutropenia, and/or thrombocytopenia. MDS is most frequently observed in the elderly population (median age between 60 and 70 years) and has a male predominance. The incidence of MDS varies from 2.1 to 12.6 cases per 100,000 people per year, with an estimated prevalence of up to 55,000 patients in the United States \[Catenacci, 2005; Williamson, 1994; Aul, 1998; Aul, 2001\]. Patients with MDS most frequently present with symptoms of fatigue, pallor, exertional dyspnea, infection, bleeding or bruising \[Catenacci, 2005\].
MDS can be divided into 2 major subtypes: indolent (or early) MDS, in which pro-apoptotic forces predominate, and aggressive (or advanced) MDS, in which pro-proliferative factors are more common.
The only curative therapy for MDS is allogeneic transplantation \[Catenacci, 2005; Thompson, 2005\]. Curative treatments are restricted to younger, healthier individuals with histocompatible-matched donors or those able to undergo intensive chemotherapeutic regimens \[Catenacci, 2005\]. Recently, the FDA approved 3 agents for the treatment of this disease, Vidaza, Dacogen, and revlimid. The latter is approved for a subset of patients with MDS with del 5q abnormality, the former two are more applicable to higher risk disease. Rhu-EPO is currently available to patients with low risk MDS however, if they fail, their options are limited to the agents mentioned above, all of which have significant myelotoxic effects. Effective and less myelosuppressive treatments for low-risk MDS are needed.
We are proposing a novel approach for the treatment of patients with low-risk MDS using heme supplementation with Panhematin® (hemin for injection). Panhematin® is an iron-containing metalloporphyrin, indicated for the amelioration of recurrent attacks of acute intermittent porphyria; it acts to limit the hepatic and/or marrow synthesis of porphyrin, presumably, as a result of the inhibition of aminolevulinic acid synthetase (the enzyme which limits the rate of porphyrin/heme biosynthetic pathway) \[Panhematin® Product Prescribing Information\].
There are pre-clinical and clinical data to suggest that heme supplementation with Panhematin® (hematin for injection) has potential as a treatment option for patients with MDS. Preliminary data indicate hemin administration has the potential to stimulate progenitor cell growth, stimulate globin synthesis, and elevate overall hemoglobin levels. Panhematin® has been proven to be well tolerated when used therapeutically in patients with acute intermittent porphyria, and it is anticipated to be well tolerated in this patient population. For this study, selected patients will have low or intermediate 1 risk disease by IPSS, and the standard of care for MDS (supportive therapies) will be administered as needed. Measurement of serum porphyrin levels and Hgb F will be done at baseline and at week 8.
MDS can be divided into 2 major subtypes: indolent (or early) MDS, in which pro-apoptotic forces predominate, and aggressive (or advanced) MDS, in which pro-proliferative factors are more common.
The only curative therapy for MDS is allogeneic transplantation \[Catenacci, 2005; Thompson, 2005\]. Curative treatments are restricted to younger, healthier individuals with histocompatible-matched donors or those able to undergo intensive chemotherapeutic regimens \[Catenacci, 2005\]. Recently, the FDA approved 3 agents for the treatment of this disease, Vidaza, Dacogen, and revlimid. The latter is approved for a subset of patients with MDS with del 5q abnormality, the former two are more applicable to higher risk disease. Rhu-EPO is currently available to patients with low risk MDS however, if they fail, their options are limited to the agents mentioned above, all of which have significant myelotoxic effects. Effective and less myelosuppressive treatments for low-risk MDS are needed.
We are proposing a novel approach for the treatment of patients with low-risk MDS using heme supplementation with Panhematin® (hemin for injection). Panhematin® is an iron-containing metalloporphyrin, indicated for the amelioration of recurrent attacks of acute intermittent porphyria; it acts to limit the hepatic and/or marrow synthesis of porphyrin, presumably, as a result of the inhibition of aminolevulinic acid synthetase (the enzyme which limits the rate of porphyrin/heme biosynthetic pathway) \[Panhematin® Product Prescribing Information\].
There are pre-clinical and clinical data to suggest that heme supplementation with Panhematin® (hematin for injection) has potential as a treatment option for patients with MDS. Preliminary data indicate hemin administration has the potential to stimulate progenitor cell growth, stimulate globin synthesis, and elevate overall hemoglobin levels. Panhematin® has been proven to be well tolerated when used therapeutically in patients with acute intermittent porphyria, and it is anticipated to be well tolerated in this patient population. For this study, selected patients will have low or intermediate 1 risk disease by IPSS, and the standard of care for MDS (supportive therapies) will be administered as needed. Measurement of serum porphyrin levels and Hgb F will be done at baseline and at week 8.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Myelodysplastic Syndrome
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Panhematin
Group Type
EXPERIMENTAL
Panhematin
Intervention Type
DRUG
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Panhematin
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
A patient will be eligible for study participation if all of the following criteria are met:
1. The patient must sign and date the IRB/IEC approved Informed Consent Form/HIPAA Authorization prior to study participation.
2. Patient is at least 18 years of age.
3. If female:
1. Patient, either male or female, is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or if of childbearing potential, must comply with an effective method of birth control acceptable to the Investigator during the study (oral contraceptives, Depo-Provera, intra-uterine device), for at least 1 month prior to enrollment and for 1 month following the completion of the study.
2. Patient is not breastfeeding.
3. Patient of childbearing potential must have a negative urine or serum pregnancy test during the screening period.
4. Patient has a diagnosis of low- or intermediate-1 risk MDS, as determined by the International Prognostic Scoring (IPSS) (score of 0-1).
5. Patient must be transfusion dependent (i.e., received ≥ 2 units over an 8-week period prior to registration) or have a hemoglobin value ≤ 10 g/dL on the screening laboratories.
6. Patients must have ≤ 10% blasts in the bone marrow and peripheral blood.
7. Patient must have a platelet counts \> 50,000/microliters and absolute neutrophil counts (ANC) \>500/microliters.
8. Patient must have adequate hepatic and renal functions, defined as serum bilirubin, serum glutamic-oxaloacetic transaminase (SGOT), and serum glutamate pyruvate transaminase (SGPT) ≤ 2 times the upper limit of normal (ULN), and creatinine ≤ 1.5 times the ULN.
9. Patient must have an ECOG score of ≤ 2.
10. The patient has a negative human immunodeficiency virus antibody (HIV) test result.
1. The patient must sign and date the IRB/IEC approved Informed Consent Form/HIPAA Authorization prior to study participation.
2. Patient is at least 18 years of age.
3. If female:
1. Patient, either male or female, is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or if of childbearing potential, must comply with an effective method of birth control acceptable to the Investigator during the study (oral contraceptives, Depo-Provera, intra-uterine device), for at least 1 month prior to enrollment and for 1 month following the completion of the study.
2. Patient is not breastfeeding.
3. Patient of childbearing potential must have a negative urine or serum pregnancy test during the screening period.
4. Patient has a diagnosis of low- or intermediate-1 risk MDS, as determined by the International Prognostic Scoring (IPSS) (score of 0-1).
5. Patient must be transfusion dependent (i.e., received ≥ 2 units over an 8-week period prior to registration) or have a hemoglobin value ≤ 10 g/dL on the screening laboratories.
6. Patients must have ≤ 10% blasts in the bone marrow and peripheral blood.
7. Patient must have a platelet counts \> 50,000/microliters and absolute neutrophil counts (ANC) \>500/microliters.
8. Patient must have adequate hepatic and renal functions, defined as serum bilirubin, serum glutamic-oxaloacetic transaminase (SGOT), and serum glutamate pyruvate transaminase (SGPT) ≤ 2 times the upper limit of normal (ULN), and creatinine ≤ 1.5 times the ULN.
9. Patient must have an ECOG score of ≤ 2.
10. The patient has a negative human immunodeficiency virus antibody (HIV) test result.
Exclusion Criteria
A patient will be ineligible for study participation if any of the following criteria are met:
1. The patient has a history of an allergic reaction or significant sensitivity to Panhematin®.
2. The patient has taken or used any investigational drug or device in the 30 days prior to screening.
3. The patient has chronic myelomonocytic leukemia (CMML).
4. The patient has a history of deep vein thrombosis or known hypercoagulable state.
5. The patient has a history of a pre-existing medical condition that, in the opinion of the investigator, will interfere with the participation in the study.
6. The patient has poor peripheral venous access, if central venous access is not available.
7. The patient has an uncontrolled active infection.
8. The patient has positive test results for hepatitis B surface antigen, and hepatitis C virus antibody.
9. The patient has any other condition or prior therapy that, in the opinion of the Investigator, would make the patient unsuitable for the study.
1. The patient has a history of an allergic reaction or significant sensitivity to Panhematin®.
2. The patient has taken or used any investigational drug or device in the 30 days prior to screening.
3. The patient has chronic myelomonocytic leukemia (CMML).
4. The patient has a history of deep vein thrombosis or known hypercoagulable state.
5. The patient has a history of a pre-existing medical condition that, in the opinion of the investigator, will interfere with the participation in the study.
6. The patient has poor peripheral venous access, if central venous access is not available.
7. The patient has an uncontrolled active infection.
8. The patient has positive test results for hepatitis B surface antigen, and hepatitis C virus antibody.
9. The patient has any other condition or prior therapy that, in the opinion of the Investigator, would make the patient unsuitable for the study.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
H. Lundbeck A/S
INDUSTRY
Sponsor Role
collaborator
Rush University Medical Center
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jamile Shammo
Associate Professor of Medicine and Pathology
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jamile Shammo, MD
Role: PRINCIPAL_INVESTIGATOR
Rush University Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rush University Medical Center
Chicago, Illinois, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Aul C, Germing U, Gattermann N, Minning H. Increasing incidence of myelodysplastic syndromes: real or fictitious? Leuk Res. 1998 Jan;22(1):93-100. doi: 10.1016/s0145-2126(97)00089-1.
Reference Type
BACKGROUND
Aul C, Giagounidis A, Germing U. Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. Int J Hematol. 2001 Jun;73(4):405-410. doi: 10.1007/BF02994001.
Reference Type
BACKGROUND
Catenacci DV, Schiller GJ. Myelodysplasic syndromes: a comprehensive review. Blood Rev. 2005 Nov;19(6):301-19. doi: 10.1016/j.blre.2005.01.004.
Reference Type
BACKGROUND
Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Lowenberg B, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Gore S, Greenberg PL; World Health Organization(WHO) international working group. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000 Dec 1;96(12):3671-4.
Reference Type
BACKGROUND
Dhar GJ, Bossenmaier I, Cardinal R, Petryka ZJ, Watson CJ. Transitory renal failure following rapid administration of a relatively large amount of hematin in a patient with acute intermittent porphyria in clinical remission. Acta Med Scand. 1978;203(5):437-43. doi: 10.1111/j.0954-6820.1978.tb14903.x.
Reference Type
BACKGROUND
Fibach E, Kollia P, Schechter AN, Noguchi CT, Rodgers GP. Hemin-induced acceleration of hemoglobin production in immature cultured erythroid cells: preferential enhancement of fetal hemoglobin. Blood. 1995 May 15;85(10):2967-74.
Reference Type
BACKGROUND
Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997 Mar 15;89(6):2079-88.
Reference Type
BACKGROUND
Mauritzson N, Albin M, Rylander L, Billstrom R, Ahlgren T, Mikoczy Z, Bjork J, Stromberg U, Nilsson PG, Mitelman F, Hagmar L, Johansson B. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia. 2002 Dec;16(12):2366-78. doi: 10.1038/sj.leu.2402713.
Reference Type
BACKGROUND
McHale CM, Winter PC, Lappin TR. Erythroid gene expression is differentially regulated by erythropoietin, haemin and delta-aminolaevulinic acid in UT-7 cells. Br J Haematol. 1999 Mar;104(4):829-37. doi: 10.1046/j.1365-2141.1999.01269.x.
Reference Type
BACKGROUND
Monette FC, Holden SA. Hemin enhances the in vitro growth of primitive erythroid progenitor cells. Blood. 1982 Aug;60(2):527-30.
Reference Type
BACKGROUND
Panhematin® Product Prescribing Information. Abbott Laboratories, August 2000 Edition
Reference Type
BACKGROUND
Porter PN, Meints RH, Mesner K. Enhancement of erythroid colony growth in culture by hemin. Exp Hematol. 1979 Jan;7(1):11-6.
Reference Type
BACKGROUND
Rund D, Ben-Yehuda D. Therapy-related leukemia and myelodysplasia: evolving concepts of pathogenesis and treatment. Hematology. 2004 Jun;9(3):179-87. doi: 10.1080/10245330410001701503.
Reference Type
BACKGROUND
Thompson JE, Luger SM. The role of hematopoietic stem cell transplantation in myelodysplastic syndrome. Oncology (Williston Park). 2005 Apr;19(4):533-42; discussion 542-4, 547-8.
Reference Type
BACKGROUND
Timonen TT, Kauma H. Therapeutic effect of heme arginate in myelodysplastic syndromes. Eur J Haematol. 1992 Nov;49(5):234-8. doi: 10.1111/j.1600-0609.1992.tb00054.x.
Reference Type
BACKGROUND
Volin L, Ruutu T, Knuutila S, Tenhunen R. Heme arginate treatment for myelodysplastic syndromes. Leuk Res. 1988;12(5):423-31. doi: 10.1016/0145-2126(88)90062-8.
Reference Type
BACKGROUND
Williamson PJ, Kruger AR, Reynolds PJ, Hamblin TJ, Oscier DG. Establishing the incidence of myelodysplastic syndrome. Br J Haematol. 1994 Aug;87(4):743-5. doi: 10.1111/j.1365-2141.1994.tb06733.x.
Reference Type
BACKGROUND
Vidaza® Product Prescribing Information. Pharmion Corporation, 5-18-04 Edition
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
06011001
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
MDS 2005-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)
NCT01822691
COMPLETED
PHASE2
A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).
NCT00946647
COMPLETED
PHASE1/PHASE2
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
NCT02093429
TERMINATED
PHASE1/PHASE2
Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)
NCT00067808
COMPLETED
PHASE2
An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS)
NCT01026376
NO_LONGER_AVAILABLE
Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)
NCT02141477
TERMINATED
PHASE1
Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)
NCT00903760
COMPLETED
PHASE2
Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT05673057
RECRUITING
PHASE1/PHASE2
Oral Clofarabine Study in Patients With Myelodysplastic Syndrome
NCT00299156
COMPLETED
PHASE2
A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)
NCT05835011
TERMINATED
PHASE2
Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes
NCT00045786
COMPLETED
PHASE2
A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes
NCT00458159
TERMINATED
PHASE1
A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome
NCT02363491
COMPLETED
PHASE1/PHASE2
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT01546038
COMPLETED
PHASE2
Lenalidomide and Decitabine in High Grade Myelodysplastic Syndromes
NCT00828802
COMPLETED
PHASE1
Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes
NCT00064974
COMPLETED
PHASE2
A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes
NCT00260065
COMPLETED
PHASE2
Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome
NCT00044382
COMPLETED
PHASE2
Decitabine in Treating Patients With Myelodysplastic Syndrome
NCT00003361
COMPLETED
PHASE2
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
NCT02469415
TERMINATED
PHASE2
An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS)
NCT00744757
COMPLETED
PHASE2
A Study of HS-20106 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
NCT06594965
NOT_YET_RECRUITING
PHASE2
Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT04402541
COMPLETED
PHASE1
A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)
NCT05568225
TERMINATED
PHASE2
Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA
NCT04798339
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2